Login
$OPK
$1.62 +$0.00 (0.07%) After hours

$OPK 8-K/A SEC Filings

Filed On Filing
28 Mar 2024 8-K/A: Regulation FD Disclosure

THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of March 27, 2024 (the “Agreement Date”), by and among BioReference Health, LLC, a Delaware limited liability company (“Seller”), Laboratory Corporation of America Holdi...

31 Oct 2023 8-K/A: Submission of Matters to a Vote of Security Holders

As previously reported, at the Annual Meeting of Stockholders of the Company held on June 22, 2023 (the “Annual Meeting”), the Company’s stockholders voted on, among other matters, a non-binding advisory vote regarding the frequency of f...

05 Feb 2021 8-K/A: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

02 Mar 2018 8-K/A: Financial Statements and Exhibits

THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT OPK—Q4 2017 OPKO Health Inc Earnings Call EVENT DATE/TIME: MARCH 01, 2018 / 9:30PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2018 Thomson Reuters. All rights rese...

05 Nov 2015 8-K/A: Financial Statements and Exhibits
08 Nov 2013 8-K/A: Financial Statements and Exhibits

On August 29, 2013, OPKO Health, Inc. (the “Company” or “OPKO”) completed its previously announced acquisition of PROLOR Biotech, Inc. (“PROLOR”), pursuant to an Agreement and Plan of Merger, dated as of April 23, 2013 (the “Merger Agree...

03 May 2013 8-K/A: Financial Statements and Exhibits

We have audited the accompanying consolidated balance sheets of Cytochroma Canada Inc. and its subsidiaries (the “Company”) as of December 31, 2011, 2010 and 2009, and the related consolidated statements of operations and deficit, change...

25 Jan 2012 8-K/A: Financial Statements and Exhibits

We have audited the accompanying balance sheet of Finetech Pharmaceutical Ltd (“the Company”) as of December 31, 2010, and the related statement of operations, changes in the shareholders’ equity and cash flows for the year ended Decembe...

14 Nov 2011 8-K/A: Financial Statements and Exhibits

We have audited the accompanying consolidated balance sheet of Claros Diagnostics, Inc. (A Development Stage Company) as of December 31, 2010 and the related consolidated statements of operations, changes in equity and comprehensive inco...

14 Nov 2011 8-K/A: Financial Statements and Exhibits

On October 11, 2011, OPKO Health, Inc. (together with certain of its subsidiaries, the “Company”) completed the sale of its ophthalmic instrumentation business (“OPKO Instrumentation”) (the “Disposition”) to Optos plc, a company incorpor...

22 Feb 2011 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On February 22, 2011, OPKO Health, Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to its Credit Agreement, dated March 27, 2007, as amended, with The Frost Group, LLC (the “Credit Agreement”). The Amendment renewed t...

14 Dec 2009 8-K/A: Financial Statements and Exhibits

The accompanying Notes 1 to 16 are an integral part of these financial statements.

27 Oct 2008 8-K/A: Financial Statements and Exhibits

For the Period from inception (June 23, 2006) to December 31, 2006

27 Oct 2008 8-K/A: Completion of Acquisition or Disposition of Assets

We have audited the balance sheets of Ophthalmic Technologies Inc. (the “Company”) as at April 30, 2007 and 2006 and the statements of operations and deficit and cash flows for the years then ended. These financial statements are the res...

12 Nov 2003 8-K/A: Changes in Registrant's Certifying Accountant; Other Events

William Fiske (Information Agent) Georgeson Shareholder Communications Inc. Banks and Brokers: (212) 440-9800 All Others Call Toll-Free: (800) 964-0733

24 Sep 2003 8-K/A: Changes in Registrant's Certifying Accountant

Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549

03 Dec 1997 8-K/A: Other Events

CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support